Alnylam Pharmaceuticalsvs.Regeneron
ALNY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.7× larger than Alnylam Pharmaceuticals by market cap; Regeneron trades at the lower P/E (19.0 vs 37.6); year to date, Regeneron leads (+7.3% vs −40.6%).
Side by side
| ALNY | REGN | |
|---|---|---|
| Market cap | $30.4B | $82.2B |
| Price | $240.08 | $833.56 |
| Today | +1.7% | +0.6% |
| Return YTD | −40.6% | +7.3% |
| Return 1Y | −48.1% | +40.5% |
| P/E | 37.6 | 19.0 |
| P/S | 6.3 | 5.3 |
| P/B | 22.4 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More ALNY & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →